Synergy Pharmaceuticals to Present at the 17th Annual BioPartnering Europe Conference in London, UK

BioPartnering Europe 2009

NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that management will present at the 17th Annual BioPartnering Europe Conference in London, UK. The Company is scheduled to present on Monday, October 12th at 11:30 AM in the Abbey Room West, 4th Floor of the Queen Elizabeth II Conference Center in London.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases, and is a majority owned subsidiary of Callisto Pharmaceuticals, Inc. (OTCBB: CLSP). Synergy’s lead drug in the clinic, SP-304 to treat gastro-intestinal disorders, recently finished a Phase I clinical trial in volunteers and the Company plans to initiate a Phase IIa clinical trial of SP-304 in chronic constipation patients in the first quarter of 2010. SP-304 is a member of a new class of non-systemic drugs for treatment of chronic constipation (CC), irritable bowel syndrome with constipation (IBS-C) and other GI diseases. SP-304 is a synthetic analog of uroguanylin, a natriuretic hormone that regulates ion and fluid transport in the GI tract. Orally administered SP-304 binds to and activates guanylate cyclase C (GC-C) expressed on epithelial cells lining the GI mucosa, resulting in augmented flow of chloride and water into the lumen of the gut, facilitating bowel movement. More information is available at http://www.synergybio.net.

Synergy Pharmaceuticals, Inc.
Gary S. Jacob, Ph.D., +1-212-297-0010
President and CEO